Table 1 Patients and treatments characteristics
From: Neutrophil count is associated with survival in localized prostate cancer
Age (y) | Â | Â |
  Median (range) | 67 | 44-87 |
PSA at diagnosis (ng/mL) | Â | |
  Median (range) | 8.1 | 0.2-132 |
AJCC tumor classification (N, %) | ||
  T1 | 1126 | 64 % |
  T2 | 627 | 32 % |
  T3 | 80 | 4 % |
Gleason score (N; %) | Â | |
  ≤6 | 930 | 53 % |
  7 | 752 | 42 % |
  ≥8 | 90 | 5 % |
NCCN risk groups (N; %) | Â | |
  Low | 748 | 42 % |
  Intermediate | 855 | 48 % |
  High | 169 | 10 % |
PPC (N, %) | Â | Â |
  <34 % | 883 | 50 % |
  ≥34 % | 883 | 50 % |
CAPRA score> | Â | |
  0-2 | 759 | 43 % |
  3-5 | 811 | 46 % |
  6-10 | 194 | 11 % |
BMI | Â | Â |
  Median (range) | 28.2 | 13.9–52.5 |
Diabetes (N; %)> | Â | |
  Yes | 272 | 15 % |
  No | 1500 | 85 % |
Statin use (N; %)> | Â | |
  Yes | 762 | 43 % |
  No | 1010 | 57 % |
CVD (N; %) | Â | |
  Yes | 629 | 35 % |
  No | 1143 | 65 % |
HTN (N; %) | Â | Â |
  Yes | 815 | 46 % |
  No | 957 | 54 % |
Lymphocytes (103 cells/μL) |  | |
  Median (range) | 1.7 | 0.4–16 |
Neutrophils (103 cells/μL) |  |  |
  Median (range) | 4.5 | 0.9–12 |
NLR | Â | Â |
  Median (range) | 3.0 | 0.1–18.4 |
Treatment characteristics | ||
Radiotherapy | Â | Â |
  HDR brachytherapy | 52 | 3 % |
  LDR brachytherapy | 901 | 51 % |
  EBRT | 815 | 46 % |
Androgen deprivation> | Â | |
  Non | 1551 | 87 % |
  Yes | 221 | 13 % |